PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems today announced that it has been notified by Roche and Trimeris that they will not be proceeding with their FDA submission for Fuzeon® to be administered with the Biojector® 2000 (“B2000”).
